An Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease
暂无分享,去创建一个
[1] Dustin L. Stwalley,et al. Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease , 2023, Crohn's & colitis 360.
[2] Runhua Han,et al. An Overlooked and Underrated Endemic Mycosis—Talaromycosis and the Pathogenic Fungus Talaromyces marneffei , 2023, Clinical microbiology reviews.
[3] Jinqiao Sun,et al. Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity , 2022, Frontiers in Cellular and Infection Microbiology.
[4] Jian Guo,et al. MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China) , 2022, Infection and drug resistance.
[5] Yaokai Chen,et al. Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China , 2022, Infectious Diseases and Therapy.
[6] Qing Wu,et al. Diagnostic performance of the metagenomic next-generation sequencing in lung biopsy tissues in patients suspected of having a local pulmonary infection , 2022, BMC Pulmonary Medicine.
[7] J. C. Hoving,et al. Key thermally dimorphic fungal pathogens: shaping host immunity , 2022, Open Biology.
[8] Zheng-tu Li,et al. Talaromyces marneffei and Mycobacterium tuberculosis co-infection in a patient with high titer anti-interferon-γ autoantibodies: a case report , 2022, BMC Infectious Diseases.
[9] Yu Qin,et al. HIV-associated talaromycosis: does timing of antiretroviral therapy matter༟. , 2021, The Journal of infection.
[10] K. Deng,et al. Environmental Risk Factors for Talaromycosis Hospitalizations of HIV-Infected Patients in Guangzhou, China: Case Crossover Study , 2021, Frontiers in Medicine.
[11] J. Chan,et al. A global call for talaromycosis to be recognised as a neglected tropical disease. , 2021, The Lancet. Global health.
[12] Y. Qiu,et al. Talaromyces marneffei and nontuberculous mycobacteria co-infection in HIV-negative patients , 2021, Scientific Reports.
[13] P. Woo,et al. Rapid Genomic Diagnosis of Fungal Infections in the Age of Next-Generation Sequencing , 2021, Journal of fungi.
[14] A. Kaltsas,et al. An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin , 2021, PLoS neglected tropical diseases.
[15] Y. Wen,et al. Gastrointestinal manifestations of Talaromyces marneffei infection in an HIV-infected patient rapidly verified by metagenomic next-generation sequencing: a case report , 2021, BMC Infectious Diseases.
[16] S. Seyedmousavi,et al. Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei , 2021, Antimicrobial Agents and Chemotherapy.
[17] S. Roytrakul,et al. Antifungal Properties of Protein Extracts from Thai Medicinal Plants to Opportunistic Fungal Pathogens , 2021, Walailak Journal of Science and Technology (WJST).
[18] Jianning Jiang,et al. Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study , 2021, Mycopathologia.
[19] Yaokai Chen,et al. Independent Risk Factors for Deaths due to AIDS in Chongqing, China: Does Age Matter? , 2021, Frontiers in Medicine.
[20] M. Kruk,et al. Considerations for a sustainability framework for neglected tropical diseases programming , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[21] Wenhong Zhang,et al. Improving Pulmonary Infection Diagnosis with Metagenomic Next Generation Sequencing , 2021, Frontiers in Cellular and Infection Microbiology.
[22] T. Le,et al. Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway , 2021, Virulence.
[23] X. Ou,et al. Clinical epidemiology and outcome of HIV‐associated talaromycosis in Guangdong, China, during 2011–2017 , 2020, HIV medicine.
[24] A. Andrianopoulos,et al. Antifungal Activity and Molecular Mechanisms of Partial Purified Antifungal Proteins from Rhinacanthus nasutus against Talaromyces marneffei , 2020, Journal of fungi.
[25] A. Chughtai,et al. Case Report: Successful Treatment of Pulmonary Talaromyces marneffei Infection with Posaconazole in a Renal Transplant Recipient. , 2020, The American journal of tropical medicine and hygiene.
[26] Yaokai Chen,et al. Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV‐infected patients with talaromycosis , 2020, Mycoses.
[27] J. Chan,et al. Occult Talaromyces marneffei Infection Unveiled by the Novel Mp1p Antigen Detection Assay , 2020, Open forum infectious diseases.
[28] S. Phongpaichit,et al. Antifungal activity of marine‐derived actinomycetes against Talaromyces marneffei , 2020, Journal of applied microbiology.
[29] E. Ashley,et al. Is stopping secondary prophylaxis safe in HIV‐positive talaromycosis patients? Experience from Myanmar , 2020, HIV Medicine.
[30] N. P. H. Lan,et al. Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] Jianping Xu,et al. Rapid and precise diagnosis of T. marneffei pulmonary infection in a HIV-negative patient with autosomal-dominant STAT3 mutation: a case report , 2020, Therapeutic advances in respiratory disease.
[32] Annapoorna Singh,et al. Localized Talaromyces marneffei infection presenting as a tonsillar mass mimicking malignancy , 2020, IDCases.
[33] S. Kajiwara,et al. Identification and functional characterization of Penicillium marneffei major facilitator superfamily (MFS) transporters , 2020, Bioscience, biotechnology, and biochemistry.
[34] K. Gough,et al. Talaromyces marneffei fungemia after travel to China in a Canadian patient with AIDS , 2020, Canadian Medical Association Journal.
[35] Tao Chen,et al. Predictive models for Talaromyces marneffei infection in HIV-infected patients using routinely collected data , 2020 .
[36] A. Andrianopoulos. Laboratory Maintenance and Growth of Talaromyces marneffei , 2020, Current protocols in microbiology.
[37] K. Ratanabanangkoon,et al. Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. , 2019, Diagnostic microbiology and infectious disease.
[38] L. Xi,et al. Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen , 2019, Mycopathologia.
[39] Yuanlin Guan,et al. Progressive Multifocal Leukoencephalopathy Diagnosed by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid in an HIV Patient , 2019, Front. Neurol..
[40] Susu He,et al. Concurrent infection with Talaromyces marneffei and Cryptococcus neoformans in a patient without HIV infection , 2019, Experimental and therapeutic medicine.
[41] M. Aguilar,et al. Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications , 2019, International journal of molecular sciences.
[42] Y. Lau,et al. Application of Flow Cytometry in the Diagnostics Pipeline of Primary Immunodeficiencies Underlying Disseminated Talaromyces marneffei Infection in HIV-Negative Children , 2019, Front. Immunol..
[43] Linlin Li,et al. Characterization of Clinical Isolates of Talaromyces marneffei and Related Species, California, USA , 2019, Emerging infectious diseases.
[44] Jianhua Hou,et al. Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis , 2019, BMC Infectious Diseases.
[45] M. Loebinger,et al. Nontuberculous Mycobacterial Pulmonary Disease , 2015 .
[46] S. Butler-Wu,et al. The Brief Case: Pneumonia Caused by Talaromyces marneffei , 2019, Journal of Clinical Microbiology.
[47] Hong Luo,et al. Evaluation of in vitro antifungal activity of osthole against Talaromyces marneffei in yeast phase , 2019 .
[48] Y. Ruan,et al. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[49] A. Andrianopoulos,et al. A unique aspartyl protease gene expansion in Talaromyces marneffei plays a role in growth inside host phagocytes , 2019, Virulence.
[50] E. Nehl,et al. Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study , 2019, Emerging microbes & infections.
[51] Achala R. Rathnayaka,et al. The world’s ten most feared fungi , 2018, Fungal Diversity.
[52] L. Ye,et al. Accuracy of rapid diagnosis of Talaromyces marneffei: A systematic review and meta-analysis , 2018, PloS one.
[53] F. Hu,et al. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[54] A. Arroliga,et al. Talaromyces marneffei infection in a non-HIV non-endemic population , 2018, IDCases.
[55] Liangxing Wang,et al. Fungemia caused by Penicillium marneffei in an immunocompetent patient with COPD , 2018, Medicine.
[56] C. Cooper,et al. Adaptation to macrophage killing by Talaromyces marneffei , 2017, Future science OA.
[57] J. Farrar,et al. A Trial of Itraconazole or Amphotericin B for HIV‐Associated Talaromycosis , 2017, The New England journal of medicine.
[58] Pingli Wang,et al. Acute Disseminated Talaromyces marneffei in An Immunocompetent Patient , 2017, Mycopathologia.
[59] Robert Schlaberg,et al. Validation of Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection. , 2017, Archives of pathology & laboratory medicine.
[60] Cunwei Cao,et al. Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study , 2017, Mycopathologia.
[61] M. Slater,et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase , 2016, Proceedings of the National Academy of Sciences.
[62] N. Tachikawa,et al. Penicillium marneffei Infection with β-D-glucan Elevation: A Case Report and Literature Review. , 2016, Internal medicine.
[63] N. P. H. Lan,et al. Development and evaluation of a real‐time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma , 2016, Mycoses.
[64] J. Jarvis,et al. HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings , 2016, Current Clinical Microbiology Reports.
[65] J. Nosanchuk,et al. A novel inhibition ELISA for the detection and monitoring of Penicillium marneffei antigen in human serum , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[66] T. Proft,et al. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing , 2016, Virulence.
[67] P. Woo,et al. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients , 2016, Emerging Microbes & Infections.
[68] G. Weinstock,et al. Making the Leap from Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in Infectious Disease Diagnostics , 2015, mBio.
[69] L. Bekker,et al. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[70] J. Perfect,et al. Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion , 2015, mBio.
[71] Ho Yee Cheung,et al. Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine , 2015, Evidence-based complementary and alternative medicine : eCAM.
[72] Hong-ru Li,et al. Diffuse interstitial and multiple cavitary lung lesions due to Talaromyces marneffei infection in a non-HIV patient , 2015, New microbes and new infections.
[73] L. Ye,et al. Single Use of Itraconazole Has No Effect on Treatment for Penicillium Marneffei with HIV Infection. , 2015, Archives of Iranian medicine.
[74] J. Wrobel,et al. Penicillium marneffei infection in a lung transplant recipient , 2015, Transplant infectious disease : an official journal of the Transplantation Society.
[75] Lingyan Qin,et al. A novel method of combining Periodic Acid Schiff staining with Wright-Giemsa staining to identify the pathogens Penicillium marneffei, Histoplasma capsulatum, Mucor and Leishmania donovani in bone marrow smears. , 2015, Experimental and therapeutic medicine.
[76] C. Liao,et al. Disseminated Penicillium marneffei mimicking paradoxical response and relapse in a non-HIV patient with pulmonary tuberculosis. , 2015, Journal of the Chinese Medical Association : JCMA.
[77] M. Strobel,et al. Penicilliosis and AIDS in Haiphong, Vietnam: evolution and predictive factors of death. , 2014, Medecine et maladies infectieuses.
[78] J. Frisvad,et al. Polyphasic taxonomy of the genus Talaromyces , 2014, Studies in mycology.
[79] M. Cuenca‐Estrella. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[80] J. Eickhoff,et al. Distinct Innate Immune Phagocyte Responses to Aspergillus fumigatus Conidia and Hyphae in Zebrafish Larvae , 2014, Eukaryotic Cell.
[81] R. Chaiwarith,et al. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study , 2013, BMC Infectious Diseases.
[82] S. Lawn,et al. Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa , 2013, PloS one.
[83] M. Bronze,et al. Clinical use of anti-TNF therapy and increased risk of infections , 2013, Drug, healthcare and patient safety.
[84] Yung-Jen Chuang,et al. Identification of Infection- and Defense-Related Genes via a Dynamic Host-Pathogen Interaction Network Using a Candida Albicans-Zebrafish Infection Model , 2013, Journal of Innate Immunity.
[85] L. Xi,et al. Penicillium marneffei Infection: An Emerging Disease in Mainland China , 2013, Mycopathologia.
[86] D. Boulware,et al. Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[87] P. Horby,et al. Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam , 2012, AIDS Research and Therapy.
[88] J. Hart,et al. Travel‐related disseminated Penicillium marneffei infection in a renal transplant patient , 2012, Transplant infectious disease : an official journal of the Transplantation Society.
[89] T. Horii,et al. E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis , 2011, Antimicrobial Agents and Chemotherapy.
[90] G. S. de Hoog,et al. Molecular identification of Penicillium marneffei using rolling circle amplification , 2011, Mycoses.
[91] N. P. H. Lan,et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[92] M. Falagas,et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[93] V. Wahn,et al. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. , 2011, Blood.
[94] P. Massip,et al. [Penicilliosis in Vietnam: a series of 94 patients]. , 2010, La Revue de medecine interne.
[95] C. Shikuma,et al. AIDS‐associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource‐limited settings. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[96] C. Ki,et al. [A case of disseminated Penicillium marneffei infection in a liver transplant recipient]. , 2010, The Korean journal of laboratory medicine.
[97] O. Tsang,et al. Disseminated Penicilliosis, Recurrent Bacteremic Nontyphoidal Salmonellosis, and Burkholderiosis Associated with Acquired Immunodeficiency Due to Autoantibody against Gamma Interferon , 2010, Clinical and Vaccine Immunology.
[98] T. Sirisanthana,et al. Application of nested PCR to detect Penicillium marneffei in serum samples. , 2009, Medical mycology.
[99] John T Brooks,et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[100] Xiao-hong Wang,et al. The effects of temperature, pH, and salinity on the growth and dimorphism of Penicillium marneffei. , 2007, Medical mycology.
[101] Hsin-Yun Sun,et al. Detection of Circulating Galactomannan in Serum Samples for Diagnosis of Penicillium marneffei Infection and Cryptococcosis among Patients Infected with Human Immunodeficiency Virus , 2007, Journal of Clinical Microbiology.
[102] Michael G. Vann,et al. In Vitro Antifungal-Drug Susceptibilities of Mycelial and Yeast Forms of Penicillium marneffei Isolates in Cambodia , 2006, Journal of Clinical Microbiology.
[103] S. Antinori,et al. Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. , 2006, Journal of travel medicine.
[104] S. Tanprawate,et al. A 12-case series of Penicillium marneffei pneumonia. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[105] T. Sirisanthana,et al. Penicillium marneffei Infection and Recent Advances in the Epidemiology and Molecular Biology Aspects , 2006, Clinical Microbiology Reviews.
[106] E. Tacconelli,et al. Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. , 2004, FEMS immunology and medical microbiology.
[107] M. Senba,et al. Clinicopathologic study of hepatic Penicillium marneffei in Northern Thailand. , 2004, Archives of pathology & laboratory medicine.
[108] K. Nishimura,et al. In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms , 2003, Antimicrobial Agents and Chemotherapy.
[109] A. Chakrabarti,et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. , 2002, The Journal of infection.
[110] K. Nelson,et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[111] K. Yuen,et al. Biotyping of Penicillium marneffeiReveals Concentration-Dependent Growth Inhibition by Galactose , 2001, Journal of Clinical Microbiology.
[112] K. Tintelnot,et al. Disseminated Penicillium marneffei infection in an African AIDS patient. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[113] K. Yuen,et al. Detection of Specific Antibodies to an Antigenic Mannoprotein for Diagnosis of Penicillium marneffeiPenicilliosis , 1998, Journal of Clinical Microbiology.
[114] K. Nelson,et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[115] K. Nelson,et al. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[116] C. H. Lee,et al. Atypical manifestations in a patient with systemic lupus erythematosus. , 1997, Journal of clinical pathology.
[117] K. Nelson,et al. Disseminated Penicillium marneffei infection in Southeast Asia , 1994, The Lancet.
[118] T. Sirisanthana,et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. , 1992, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[119] G. Piérard,et al. IMMUNOHISTOCHEMICAL IDENTIFICATION OF PENICILLIUM MARNEFFEI BY MONOCLONAL ANTIBODY , 1992, International journal of dermatology.
[120] D. Tsang,et al. Disseminated Penicillium marneffei infection in HIV‐infected subject , 1992, Histopathology.
[121] Y. Chan,et al. Ultrastructural observations on Penicillium marneffei in natural human infection. , 1990, Ultrastructural pathology.
[122] L. Ajello,et al. Infection caused by Penicillium marneffei: description of first natural infection in man. , 1973, American journal of clinical pathology.
[123] R. Lehrer,et al. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. , 1969, The Journal of clinical investigation.
[124] G. Ségretain. [Penicillium marneffei n.sp., agent of a mycosis of the reticuloendothelial system]. , 1959, Mycopathologia et mycologia applicata.
[125] P. Sureau,et al. [Penicillosis from Rhizomys sinensis]. , 1956, Bulletin de la Societe de pathologie exotique et de ses filiales.
[126] A. Chaiprasert,et al. Penicillium marneffei: types and drug susceptibility , 2004, Mycopathologia.
[127] F. Dromer,et al. Antifungal drug resistance in pathogenic fungi. , 1998, Medical mycology.
[128] T. Sirisanthana,et al. Infection due to Penicillium marneffei. , 1997, Annals of the Academy of Medicine, Singapore.